# Ellacor® Micro-Coring Technology® in Fitzpatrick Skin Types I-VI, Including Patients Receiving Glucagon-Like Peptide-1 Receptor Agonists

> **NCT07224880** · — · RECRUITING · sponsor: **Cytrellis Biosystems, Inc.** · enrollment: 10 (estimated)

## Conditions studied

- glp1 Agonist
- Gene Expression
- Skin Laxity

## Interventions

- **DEVICE:** ellacor

## Key facts

- **NCT ID:** NCT07224880
- **Lead sponsor:** Cytrellis Biosystems, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** RECRUITING
- **Start date:** 2025-10-14
- **Primary completion:** 2026-01-30
- **Final completion:** 2026-02-28
- **Target enrollment:** 10 (ESTIMATED)
- **Last updated:** 2025-12-31


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07224880

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07224880, "Ellacor® Micro-Coring Technology® in Fitzpatrick Skin Types I-VI, Including Patients Receiving Glucagon-Like Peptide-1 Receptor Agonists". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT07224880. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*